- Trials with a EudraCT protocol (733)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
733 result(s) found for: Induction chemotherapy.
Displaying page 1 of 37.
EudraCT Number: 2016-001533-28 | Sponsor Protocol Number: AAML0531 | Start Date*: 2016-05-03 |
Sponsor Name:Children's Oncology Group | ||
Full Title: A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults | ||
Medical condition: Acute myeloid leukaemia | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2014-001633-84 | Sponsor Protocol Number: CFZ008 | Start Date*: 2015-01-22 | |||||||||||
Sponsor Name:Onyx Therapeutics, Inc. | |||||||||||||
Full Title: Phase 1b/2 Study of Carfilzomib in Combination with Dexamethasone, Mitoxantrone, PEG-asparaginase, and Vincristine (UK R3 Induction Backbone) in Children with Relapsed or Refractory Acute Lymphobla... | |||||||||||||
Medical condition: Relapsed or Refractory Acute Lymphoblastic Leukemia | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) GB (GB - no longer in EU/EEA) ES (Temporarily Halted) FR (Completed) AT (Completed) DK (Prematurely Ended) NL (Completed) SE (Completed) GR (Completed) PL (Completed) PT (Completed) BG (Completed) NO (Completed) CZ (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-004856-24 | Sponsor Protocol Number: AC220-A-U302 | Start Date*: 2016-09-02 | |||||||||||
Sponsor Name:Daiichi Sankyo, Inc. | |||||||||||||
Full Title: A Phase 3, Double-Blind, Placebo-controlled Study of Quizartinib Administered in Combination with Induction and Consolidation Chemotherapy, and Administered as Continuation Therapy in Subjects 18 t... | |||||||||||||
Medical condition: FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) (+) acute myeloid leukemia (AML) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) CZ (Completed) DE (Completed) HU (Completed) ES (Ongoing) RO (Ongoing) BE (Completed) PT (Completed) BG (Completed) HR (Completed) EE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002919-18 | Sponsor Protocol Number: AC220-A-U202 | Start Date*: Information not available in EudraCT | |||||||||||||||||||||
Sponsor Name:Daiichi Sankyo, Inc. | |||||||||||||||||||||||
Full Title: A Phase 1/2, Multicenter, Dose-Escalating Study To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy Of Quizartinib Administered in Combination with Re-Induction Chemotherapy, a... | |||||||||||||||||||||||
Medical condition: Relapsed or Refractory acute myeloid leukemia (AML) in subjects aged ≥1 month to ≤21 years with FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) mutations following failure of fr... | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: IE (Prematurely Ended) FR (Trial now transitioned) DK (Trial now transitioned) ES (Ongoing) BE (Trial now transitioned) SE (Trial now transitioned) NL (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Trial now transitioned) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-004977-12 | Sponsor Protocol Number: MO19872 | Start Date*: 2006-06-22 |
Sponsor Name:F. Hoffmann-La Roche Limited | ||
Full Title: A Phase IIIb study of MabThera® (rituximab) maintenance therapy in patients with follicular Non-Hodgkin’s Lymphoma who have responded to induction therapy. | ||
Medical condition: Follicular non Hodgkin's Lymphoma (NHL) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SI (Completed) FI (Completed) SE (Completed) SK (Completed) IT (Completed) GR (Completed) DE (Completed) ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-001711-85 | Sponsor Protocol Number: PTF202 | Start Date*: 2022-03-10 | |||||||||||
Sponsor Name:PentixaPharm GmbH | |||||||||||||
Full Title: A prospective, international, multi-centre, open-label,single-arm phase II study investigating the predictive value of [68Ga]Ga-PentixaFor PET imaging in primary and isolated secondary CNS lymphom... | |||||||||||||
Medical condition: Central nervous system (CNS) lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) DK (Prematurely Ended) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-005422-30 | Sponsor Protocol Number: AIO-KRK-0212 | Start Date*: 2014-01-09 | |||||||||||
Sponsor Name:AIO Studien gGmbH | |||||||||||||
Full Title: Randomized Phase II study for evaluation of efficacy and safety of maintenance treatment with 5-FU/FA plus panitumumab vs. 5-FU/FA alone after prior induction treatment with mFOLFOX6 plus panitumum... | |||||||||||||
Medical condition: Metastatic colorectal cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-001363-12 | Sponsor Protocol Number: TRIANGLE | Start Date*: 2016-03-24 | |||||||||||||||||||||
Sponsor Name:Klinikum der Universität München, Medizinische Klinik und Poliklinik III | |||||||||||||||||||||||
Full Title: autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma – a randomized European MCL Network trial | |||||||||||||||||||||||
Medical condition: Generalized mantle cell Lymphoma | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Trial now transitioned) SE (Trial now transitioned) DK (Trial now transitioned) NL (Trial now transitioned) BE (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) FI (Trial now transitioned) CZ (Trial now transitioned) PT (Trial now transitioned) IT (Trial now transitioned) HR (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000624-33 | Sponsor Protocol Number: HO156_AMLSG28/18 | Start Date*: 2019-08-01 | ||||||||||||||||
Sponsor Name:HOVON Foundation | ||||||||||||||||||
Full Title: A phase 3, multicenter, open-label, randomized, study of gilteritinib versus midostaurin in combination with induction and consolidation therapy followed by one-year maintenance in patients with ne... | ||||||||||||||||||
Medical condition: Previously untreated Acute Myeloid Leukemia (AML) or Myelodysplastic syndromes with excess blasts-2 (MDS-EB2) with FLT3 mutations | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Trial now transitioned) SE (Trial now transitioned) LT (Trial now transitioned) BE (Trial now transitioned) FI (Trial now transitioned) FR (Trial now transitioned) IE (Trial now transitioned) AT (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-006657-27 | Sponsor Protocol Number: CAIRO3 | Start Date*: 2007-01-11 |
Sponsor Name:Dutch Colorectal Cancer Group | ||
Full Title: Maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with capecitabine, oxaliplatin, and bevacizumab as first-line treatment in patients with advance... | ||
Medical condition: Advanced colorectal carcinoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-002202-20 | Sponsor Protocol Number: 213400 | Start Date*: 2020-12-07 | ||||||||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Ltd. | ||||||||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants Whose Dise... | ||||||||||||||||||
Medical condition: Non-small Cell Lung Cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Trial now transitioned) NL (Trial now transitioned) DE (Trial now transitioned) NO (Trial now transitioned) BE (Trial now transitioned) GR (Trial now transitioned) HU (Trial now transitioned) BG (Trial now transitioned) IT (Trial now transitioned) PL (Trial now transitioned) RO (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-000328-47 | Sponsor Protocol Number: CV185-155 | Start Date*: 2015-09-15 | ||||||||||||||||
Sponsor Name:Bristol-Myers Squibb | ||||||||||||||||||
Full Title: A Phase III Randomized, Open Label, Multi-center Study of the Safety and Efficacy of Apixaban for Thromboembolism Prevention versus No Systemic Anticoagulant Prophylaxis during Induction Chemothera... | ||||||||||||||||||
Medical condition: Lymphoma, Acute Lymphoblastic Leukemia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: Outside EU/EEA BE (Completed) PL (Completed) CZ (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2018-001076-38 | Sponsor Protocol Number: GMI-1271-301 | Start Date*: 2018-12-21 | |||||||||||
Sponsor Name:GlycoMimetics, Inc. | |||||||||||||
Full Title: A Phase III Randomized, Double-Blind Trial to Evaluate the Efficacy of Uproleselan Administered with Chemotherapy versus Chemotherapy Alone in Patients with Relapsed/Refractory Acute Myeloid Leukemia | |||||||||||||
Medical condition: Acute Myeloid Leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Prematurely Ended) NL (Prematurely Ended) ES (Ongoing) IT (Prematurely Ended) FR (Prematurely Ended) GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-003540-21 | Sponsor Protocol Number: CPKC412E2301 | Start Date*: 2018-05-23 |
Sponsor Name:Novartis Pharma AG | ||
Full Title: A phase III, randomized, double-blind study of chemotherapy with daunorubicin or idarubicin and cytarabine for induction and intermediate dose cytarabine for consolidation plus midostaurin (PKC412... | ||
Medical condition: newly diagnosed FLT3 non-mutated acute myeloid leukemia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) BE (Completed) IT (Completed) PT (Completed) FR (Completed) NO (Completed) ES (Prematurely Ended) AT (Completed) HU (Prematurely Ended) BG (Completed) PL (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-002853-13 | Sponsor Protocol Number: EWALL-BOLD | Start Date*: 2018-03-01 | |||||||||||
Sponsor Name:Goethe Universität Frankfurt | |||||||||||||
Full Title: Phase II trial for the treatment of older patients with newly diagnosed CD19 positive, Ph/BCR-ABL negative B-precursor acute lymphoblastic leukemia with sequential dose reduced chemotherapy and Bli... | |||||||||||||
Medical condition: Patient aged 56 and 74 with CD19 positive, Ph/BCR-ABL negative B-precursor acute lymphoblastic leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003632-23 | Sponsor Protocol Number: IC2019-02 | Start Date*: 2020-06-17 | |||||||||||
Sponsor Name:Institut Curie | |||||||||||||
Full Title: LOC-R01: Randomized Phase IB/II Study of escalating doses of Lenalidomide and Ibrutinib in association with R-MPV as a targeted induction treatment for patients aged 18 to 60 with a newly diagnosed... | |||||||||||||
Medical condition: Primary Central Nervous System Lymphoma (PCNSL) in patients aged 18 to 60, in first-line treatment | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-019562-91 | Sponsor Protocol Number: GS-EU-131-0247 | Start Date*: 2010-12-13 | |||||||||||
Sponsor Name:Gilead Sciences International Ltd | |||||||||||||
Full Title: A Phase 3, Double-Blind, Multicenter, Randomized, Placebo Controlled Study to Assess the Efficacy, Safety and Tolerability of Prophylactic Liposomal Amphotericin B (AmBisome®) for the Prevention of... | |||||||||||||
Medical condition: Invasive fungal infections (IFI) in subjects with Acute Lymphoblastic Leukemia (ALL) undergoing remission induction chemotherapy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) PT (Completed) ES (Completed) DE (Completed) GR (Completed) BE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-000891-34 | Sponsor Protocol Number: ERA2006001 | Start Date*: 2006-05-05 |
Sponsor Name:Hôpital Ambroise Paré | ||
Full Title: A randomized, international, open-label, phase II study of peripheral blood progenitor cell (PBPC) mobilization and engraftment with pegfilgrastim or filgrastim for autologous transplantation in su... | ||
Medical condition: Multiple Myeloma . | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2014-005595-28 | Sponsor Protocol Number: AIO-TRK-0214 | Start Date*: 2015-09-29 | |||||||||||
Sponsor Name:AIO-Studien-gGmbH | |||||||||||||
Full Title: Induction therapy with gefitinib followed by taxane platinum chemotherapy and intercalated gefitinib in NSCLC stages II-IIIB with activating EGFR mutation – A single arm Phase II trial. | |||||||||||||
Medical condition: Patients with stage II, IIIA and IIIB non-squamous non-small-cell lung cancer with activating EGFR mutation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-004577-14 | Sponsor Protocol Number: Blina-CELL | Start Date*: 2018-12-05 | |||||||||||
Sponsor Name:Ústav hematologie a krevní transfuze | |||||||||||||
Full Title: Single cycle of blinatumomab followed by high-dose chemotherapy in the induction therapy for Ph-negative acute lymphoblastic leukemia in adults. | |||||||||||||
Medical condition: Newly diagnosed, previously untreated, Ph-negative B-precursor acute lymphoblastic leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
